In order to take account of the variety of the statutory tasks of the Agency and of the rapporteurs and, where applicable, co-rapporteurs, for costs relating to the assessment of medicinal products for human use and for veterinary medicinal products, fees should be levied per procedure. For costs incurred by the Agency for other ongoing activities that it carries out under its mandate that benefit marketing authorisation holders overall, fees should be levied on an annual basis. For the purpose of simplification, the costs related to minor variations of Type I and to renewals should be included in the annual fee on the basis of an average estimation.
Recital 15, Regulation (EU) 2024/568
In forcesince 7 Feb 2024